Q-Ventures Program II (Co-Invest Holdings) Ltd. 4

4 · Vir Biotechnology, Inc. · Filed Oct 18, 2019

Form 4Exit

Period: 2019-10-16

Other

Transactions

Conversion
Common Stock
[F2][F1]
2019-10-16+1,111,111→ 1,111,111 total
Conversion
Common Stock
[F3][F1]
2019-10-16+555,555→ 1,666,666 total
Conversion
Series A-1 Convertible Preferred Stock
[F2][F1]
2019-10-16−1,111,111→ 0 total
→ Common Stock (1,111,111 underlying)
Conversion
Series B Convertible Preferred Stock
[F3][F1]
2019-10-16−555,555→ 0 total
→ Common Stock (555,555 underlying)

Footnotes (3)

[F1]The reported securities are beneficially owned by Q-Ventures Program II (Co-Invest Holdings) Ltd. ("Q-Ventures"). Frank Angella and Christopher Quinn are the directors of Q-Ventures and have shared voting and investment power over the shares held by Q-Ventures and, as a result, may each be deemed to beneficially own the reported securities. Each of the Reporting Persons disclaims beneficial ownership of the reported securities, except to the extent of his or its pecuniary interest therein.
[F2]The Series A-1 Convertible Preferred Stock ("Series A") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the Issuer's public offering of Common Stock pursuant to the Issuer's registration statement under the Securities Act of 1933, as amended, filed with the Securities and Exchange Commission on September 3, 2019, as amended on September 30, 2019 (the "IPO"). The Series A had no expiration date.
[F3]The Series B Convertible Preferred Stock ("Series B") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the IPO. The Series B had no expiration date.

Signature

/s/ Frank Angella as an authorized signatory of each Reporting Person|2019-10-18

Documents

1 file